Cumberland Pharmaceuticals Reports 12% Revenue Growth in 2025

Cumberland Pharmaceuticals reported a 12% year-to-date revenue increase, reaching US$30.8 million for the first nine months of 2025, compared with US$27.4 million during the same period in 2024. Third-quarter net revenues totaled US$8.3 million.

“We are pleased to add an established, FDA-approved brand to our commercial portfolio,” says A.J. Kazimi, CEO, Cumberland Pharmaceuticals. “As we move into the final quarter of 2025, we remain focused on providing unique products that improve patient care.”

Growth was supported by new partnerships and portfolio expansion. In 3Q25, Cumberland formed a joint commercialization venture with RedHill Biopharma Ltd. for Talicia, an FDA-approved treatment for Helicobacter pylori infection. The companies established Talicia Holdings, Inc., with RedHill holding 70% and Cumberland 30% ownership. Cumberland will lead US sales and distribution, with both firms sharing net revenues equally.

International operations also advanced. Cumberland launched Vibativ in Saudi Arabia through Tabuk Pharmaceutical Manufacturing Company and obtained regulatory approval for its ibuprofen injection in Mexico through PiSA Farmacéutica. Vibativ also received approval in China earlier this year.

In the United States, Cumberland expanded Vibativ’s reach through Vizient Inc. and Premier Inc., increasing hospital and outpatient access nationwide. The company also continued its ifetroban clinical program for rare diseases, including Duchenne muscular dystrophy (DMD). Phase II study results showed a 5.4% improvement in cardiac function among high-dose DMD patients, with findings submitted to the FDA.

Third-quarter product revenues included US$3.2 million from Sancuso, US$2.6 million from Vibativ, US$1.2 million from Kristalose, and US$0.9 million from Caldolor. Operating expenses were US$10.3 million for the quarter and US$32.3 million year-to-date. The company reported a quarterly net loss of US$1.9 million and a nine-month net loss of US$1.4 million, though adjusted earnings reached US$1.9 million, or US$0.13 per diluted share.

As of Sept. 30, Cumberland held US$66 million in total assets, including US$15 million in cash, and reported US$26 million in shareholders’ equity.